SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending following the FDA approval of YARTEMLEA, making it the first and only approved therapy for the life-threatening transplant-associated thrombotic microangiopathy (TA-TMA). The community is celebrating this significant milestone, with discussions centered on the stock's perceived undervaluation, potential for a short squeeze, and heightened speculation around a buyout, especially given a prior licensing deal with Novo Nordisk.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending following a recent clinical trial failure for its depression drug, a development released during a holiday period that drew community criticism for its timing. However, investor attention is quickly shifting to the company's robust pipeline, particularly upcoming data for its epilepsy, obesity, and oncology programs. Significant insider buying after a recent offering has also fueled renewed confidence, signaling a belief in future growth despite prior regulatory setbacks.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending sharply higher following the announcement of its acquisition by Sanofi, significantly boosting Sanofi's adult immunization portfolio with Heplisav-B and a promising shingles vaccine candidate. While many long-term investors express disappointment over the agreed price, viewing it as an undervaluation, others are relieved to see an exit after years of holding amid prior discussions about management's performance and shareholder value.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu (SHIB) is trending with highly polarized community sentiment as investors debate its immediate future. Many loyal holders view recent price action as a prime accumulation opportunity, anticipating a strong rally, while a vocal contingent labels it a "scam" or "shitcoin" and questions its underlying value. This prominent meme coin continues to generate significant conversation regarding its potential amidst broader market volatility.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is a trending topic after reporting robust earnings, showcasing a critical milestone with its first positive adjusted EBITDA, coupled with increased revenue guidance that signals continued growth in AI-driven precision medicine. Despite these strong results and several analyst upgrades, the community is actively debating recent price volatility, with many expressing long-term conviction in the company's AI-driven healthcare platform while others point to "sell the news" dynamics and market manipulation.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

ATOM is trending as community discussion intensifies around its 'Internet of Blockchains' model versus emerging, compliance-first infrastructure like Keeta, which boasts high throughput for institutional finance. Many holders are debating ATOM's long-term value and recent price stagnation, even as a significant tokenomics redesign aims to shift towards a revenue-based model, highlighting a broader market focus on both foundational interoperability and specialized, high-performance settlement layers.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is gaining attention for its central role in Co-Packaged Optics (CPO) and Silicon Photonics, supplying crucial components for TSMC's COUPE platform, which is integral to advanced AI chips from major players like NVIDIA and AMD. The community is highly engaged, discussing the immense future revenue potential from this technology and emerging AR/AI applications, though some express impatience regarding the timeline for these innovations to significantly impact the company's financial results.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is trending as recent developments, including the closure of a public offering and significant technical validations like graduating Shell's GameChanger program and successful steam-cracking trials, energize investors. Community discussion highlights the company's de-risking milestones and vast market potential for its Hydrochemolytic technology, though skeptics continue to challenge its economic viability and commercial pathway.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

Opgen (OPGN OTC) is trending due to its strategic pivot towards an AI-driven fintech platform, CapForce, which is generating significant community discussion around a potential Nasdaq relisting. Investors are closely watching recent SEC filings and the substantial insider ownership from AEI Capital, fueling speculation of a major valuation increase for this low-float stock focused on Asian digital investment banking.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens (XLM) is drawing significant attention due to its expanding institutional utility, highlighted by U.S. Bank testing stablecoin issuance and PayPal's PYUSD stablecoin adoption on its network, alongside strategic upgrades enhancing its enterprise appeal. The community is actively discussing XLM's potential for a significant rebound, viewing its advancements in cross-border payments and regulatory compliance as key drivers, while also observing emerging high-throughput infrastructure like Keeta as a complementary force in the evolving digital finance ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AVDL DUBLIN - Morgan Stanley &amp; Co. LLC disclosed Wednesday its trading activity in Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares, according to a regulatory filing with the Irish Takeover Panel. 
The filing, made under Rule 38.5(a) of the Irish Takeover Panel Act, revealed that Morgan Stanley, acting as an exempt principal trader with recognized intermediary status, purchased 167,717 ordinary shares of Avadel Pharmaceuticals on December 9, 2025. The shares were acquired at prices ranging from $21.29 to $21.33 per share. 
On the same day, Morgan Stanley sold 167,737 Avadel shares at prices between $21.29 and $21.33 per share. 
The disclosure identifies Morgan Stanley as connected to Avadel Pharmaceuticals in relation to an unspecified offer or potential transaction. The filing did not include any cash-settled derivative transactions, stock-settled derivative transactions, or other dealings in Avadel securities.

StockTwits Web

Avadel Pharm Sp ADR

 DUBLIN - Morgan Stanley & Co. LLC disclosed Wednesday its trading activity in Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares, according to a regulatory filing with the Irish Takeover Panel. 
The filing, made under Rule 38.5(a) of the Irish Takeover Panel Act, revealed that Morgan Stanley, acting as an exempt principal trader with recognized intermediary status, purchased 167,717 ordinary shares of Avadel Pharmaceuticals on December 9, 2025. The shares were acquired at prices ranging from $21.29 to $21.33 per share. 
On the same day, Morgan Stanley sold 167,737 Avadel shares at prices between $21.29 and $21.33 per share. 
The disclosure identifies Morgan Stanley as connected to Avadel Pharmaceuticals in relation to an unspecified offer or potential transaction. The filing did not include any cash-settled derivative transactions, stock-settled derivative transactions, or other dealings in Avadel securities.

Fred Sanford

@Fred_G_Sanford can someone explain what this means, curious why would buy and then sell same # of shares

 can someone explain what this means, curious why would buy and then sell same # of shares

Jason Harris

@SimplyJrox I think it may mean that someone is about to make a new superior offer

 I think it may mean that someone is about to make a new superior offer

@Fred_G_Sanford @SimplyJrox 

Perhaps they got an interested bidder on same day they bought shares which forced them to dispose of them given their intimate knowledge of the M&amp;A process.   I don’t have another explanation

StockTwits for iOS

 

Perhaps they got an interested bidder on same day they bought shares which forced them to dispose of them given their intimate knowledge of the M&A process.   I don’t have another explanation

Everest17

@Fred_G_Sanford Maybe it’s a coded message. Potential bid of +$4 over current cash offer ”buy sell spread” cents to $. + CVR based on difference in shares 10 shares to 1$.  That would equate to a 2.97 billion based on shares implied. Much closer to what ALKS   should have started at. That is 120% of current offer and ironically we had roughly a 1.2% gain at today’s high. This is not finantial advice. Just bored and playing with numbers $AVDL

Its_Only_Money_369

 Maybe it’s a coded message. Potential bid of +$4 over current cash offer ”buy sell spread” cents to $. + CVR based on difference in shares 10 shares to 1$.  That would equate to a 2.97 billion based on shares implied. Much closer to what ALKS   should have started at. That is 120% of current offer and ironically we had roughly a 1.2% gain at today’s high. This is not finantial advice. Just bored and playing with numbers 